Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 15, 2013
Grant Date -
May 9, 2013
app pub date -
Jun 10, 2011
filing date -
Jun 15, 2010
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention is directed to heterocyclic fused phenanthrolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully